WO2005120616A1 - Securing dose quality of inhalable drug - Google Patents
Securing dose quality of inhalable drug Download PDFInfo
- Publication number
- WO2005120616A1 WO2005120616A1 PCT/SE2005/000843 SE2005000843W WO2005120616A1 WO 2005120616 A1 WO2005120616 A1 WO 2005120616A1 SE 2005000843 W SE2005000843 W SE 2005000843W WO 2005120616 A1 WO2005120616 A1 WO 2005120616A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- inhaler
- dose
- slide
- container
- motion
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/06—Solids
- A61M2202/064—Powder
Definitions
- the present invention relates to a method and a device applied in a single dose dry powder inhaler for bringing a medicament dose into the dry powder inhaler in preparation of an inhalation of the dose being enclosed in a sealed dose container.
- MDIs metered dose inhalers
- DPIs dry powder inhalers
- MDIs use medicaments in liquid form and may use a pressurized drive gas to release a dose.
- MDIs have a relatively low capacity for delivering an effective dose of the active substance in a single inhalation and many devices have problems with using a drive gas, which is environmentally acceptable.
- Nebulizers are fairly big, non-portable devices. Dry powder inhalers have become more and more accepted in the medical service, because they deliver an effective dose in a single inhalation, they are reliable, often quite small in size and easy to operate for a user.
- Multi-dose devices Two types are common, multi-dose dry powder inhalers and single dose dry powder inhalers.
- Multi-dose devices have the advantage that a quantity of medicament powder, enough for a large number of doses, is stored inside the inhaler and a dose is metered from the store shortly before it is supposed to be inhaled.
- Single dose inhalers either require reloading after each administration or they may be loaded with a limited number of individually packaged doses, where each package is opened shortly before inhalation of the enclosed dose is supposed to take place.
- Gelatin or plastic capsules and blisters made of aluminum or plastic, or laminates comprising aluminum and plastic foil are common prior art containers for metered single doses of dry powder medicaments.
- the user has to open the inhaler, insert at least one container into the inhaler, close it, push a button to force one or more sharp instrument(s) to penetrate a selected container, such that the dose may be accessed by streaming air when the user at leisure decides to inhale the dose.
- the most common method of opening the container is to punch one or more holes in the container itself or in a foil sealing the container.
- the powder is poured onto a surface inside the inhaler and made available for inhalation from there.
- the dose is aerosolized by inhalation air being forced through the container or the dose being shaken out of the container and immediately aerosolized' by streaming air on the outside of the container.
- a method of making a metered dry powder medication dose, enclosed in a dose container, accessible for inhalation with a minimum of exposure to ambient atmosphere and a hand-operated device for carrying out the method are disclosed.
- the present invention relates to a single dose inhaler, which is provided with a movable inhaler member, a so called slide, which has at least one matching receptacle adapted for receiving a selected type of dose container.
- the slide is movable between a first, protuding position, where the receptacle(s) is accessible for loading of a sealed dose container by a user, and a second, retracted position inside the inhaler.
- the slide carrying an unopened, sealed dose container is arranged to be pushed by a user's hand force from the first position to the second position. During the motion the seal of the dose container is opened by an opening member provided inside the inhaler.
- an inhalation-induced flow element e.g. directed by a suction nozzle being in close proximity to the dose as it, too, moves into the inhaler carried by the slide.
- the inhaler is provided with a breath-actuated latch mechanism preventing the slide from being pushed from the first position, if the receptacle is loaded with a dose container, unless a suction exceeding a certain minimum magnitude is provided by the user sucking at a mouthpiece of the inhaler.
- This breath-actuation helps the user to synchronize the pushing action with an act of inhalation.
- FIG. 1 illustrates in a flow diagram a particular method of the present invention
- FIG. 2 illustrates a slide applied in a single dose dry powder inhaler in a top view with slide in a protruding position (Fig. 2a) and slide in a retracted position (Fig. 2b) and a side view (Fig. 2c) of slide and inhaler;
- FIG. 3 illustrates a sealed dose container carrying an enclosed dose adapted for the slide in Fig. 2;
- FIG. 4 illustrates in perspective (Fig. 4a), top (Fig. 4b) and front (Fig. 4c) views a particular embodiment of a sealed dose container, adapted for the present invention.
- FIG. 5 illustrates two typical inhalation sequences (Fig 5a and Fig. 5b) when applying the present invention to a dry powder inhaler.
- the present invention relates to a method and a device for making a metered dry powder medication dose in a dose container accessible inside a dry powder inhaler (DPI) in direct connection with an inhalation of the enclosed dose.
- DPI dry powder inhaler
- the method comprises bringing a sealed container carrying a single medicament dose into the inhaler by means of a movable inhaler member, a so called slide.
- a user has access to the slide in a first, protruding position.
- the slide comprises at least one matching receptacle designed for a particular type of dose container.
- the user pushes the slide into the inhaler while at the same time inhaling through a mouthpiece of the inhaler.
- the container seal begins to be opened up by an opener device integrated in the inhaler, thereby letting ambient air into the container and into the dose powder. But at the same time one or more flow elements of the inhaler gains access to the dose and a concurrent release of the dose into an inhalation air-stream begins.
- the time lapse between opening of the seal and dose release is extremely short, which secures the quality of the dose when delivered to the inhaling user.
- the time the particles of the dose are exposed to the atmosphere before they are entrained into inspiration air is only a split second.
- the slide When the slide reaches a second, fully retracted position, the dose has already been delivered. Preferably, however, the slide cannot move from the first position unless a sufficiently strong inhalation is already in progress.
- the transport, container opening and dose delivery are carried out in a single user-initiated action. In this way, the dose is exposed to the atmosphere for a minimum time, in fact only for the duration of a complete dose delivery. The exposure of the dose to the atmosphere is consistently short every time and actually less than the inhalation time itself.
- the slide 15 is provided with at least one matching receptacle 16 for a selected type of single dose container 33 in a protective casing 41. Only the defined selected type of dose container 33+41 can be inserted into the receptacle. After the dose has been delivered the slide remains in the second, retracted position until the user activates the slide, such that it comes out of the inhaler 12 carrying the now spent empty container. The user removes the spent container 33+41 and discards it. Pushing the slide without container back into the inhaler closes the inhaler shut. The user may activate the slide as needed when the time comes for administering a new dose.
- this novel method of protecting a dose and bringing it into an inhaler 12, having a mouthpiece 11 makes it possible to arrange a very efficient, high quality dose delivery with negligible risk of dose degradation and of foreign matter being accidentally introduced into the inhaler by the user.
- a movable inhaler member constituting a slide, being in a normal, fully retracted position inside the inhaler body, is activated in an optional step 100 by e.g. a pushbutton accessible on the inhaler.
- the slide is held in the fully retracted position by a latch mechanism, so that it cannot move until the latch is released by any suitable means, e.g. a spring loaded pushbutton.
- a latch mechanism so that it cannot move until the latch is released by any suitable means, e.g. a spring loaded pushbutton.
- the slide when the slide is released it will come out of the inhaler automatically, i.e. without further assistance from a user, into a first, fully protruding, dose loading position, step 110, where the slide is ready to accept at least one dose container.
- the inhaler has been used before, it is possible that a spent container is still held in at least one receptacle in the slide and must be removed before a new one can be fitted.
- a new, selected container of the correct type may now be snapped into the matching receptacle, step 120.
- the container snaps into place and remains firmly held there, with no possibility of moving relative the slide.
- the slide is now pushed inwards into the inhaler, step 140, bringing the container with it.
- step 150 As the container enters the inhaler body it is opened, step 150, by suitable opening means and a stream of air is then directed to the dose by an adapted flow element, e.g. a suction nozzle, step 160.
- an adapted flow element e.g. a suction nozzle
- the container is opened while being transported into the inhaler.
- the container may be opened when the slide reaches its second, fully retracted position, or proximate this position, inside the inhaler. See Figure 5 which illustrates a typical opening of a container synchronized with an inhalation.
- Diagram curve Y represents the suction power in kPa provided by the user over time X
- curve Z represents the container motion from 0 (starting position) to 100 % (end position) in the DPI.
- the bringing of the slide with a dose container into the inhaler is synchronized to a commenced inhalation, such that the time during which the dose is exposed to the ambient atmosphere is minimized.
- the container must be opened before a stream of air can access the dose.
- the container starts to be opened at a predetermined point along the stroke made by the slide. A stream of inspiration air is directed into the container as it is being opened, whereby the air-stream gains access to the enclosed dose.
- the disclosed method must be adapted to the particular type of dose container, which has been selected for insertion into a particular, adapted dry powder inhaler.
- the receptacle in the slide, firmly holding the dose container must be adapted and matched to the container type.
- the piercing or opening members and the flow elements inside the inhaler must also be adapted for the container type.
- the air flow resulting from an inhalation is directed by proper channeling into the dose container, preferably as soon as the container is being opened by the piercing or opening members of the inhaler, such that the stream of air may release the dose and bring the dose into the inspiration air of a user without unnecessary delay.
- different types of dose containers may be selected and advantageously used in the present invention.
- containers are aluminum or plastic single dose blisters of varying size and design and also capsules of gelatin, cellulose or plastics.
- a person of ordinary skill in the art will know how to adapt the receptacle in the slide, the insertion of the dose container into the inhaler and the inhaler itself, including the piercing or cutting members and air flow channels, to a particular type of dose container.
- the disclosed method eliminates as far as possible any adverse influence that e.g. humidity in the air may have on the fine particles in the dose, such as creating particle aggregates and making aggregates more difficult to de- aggregate when sucked up and delivered to a user of the inhaler.
- Minimizing the dose exposure to the atmosphere may preferably be done by implementing a breath actuation mechanism in the inhaler.
- the breath actuation blocks the bringing of the slide and container into the inhaler until the user applies at least a minimum suction power to a mouthpiece of the inhaler.
- a pressure sensitive flap may be arranged to open when the applied suction is strong enough, thus letting air flow into the air channels of the inhaler, which are in fluid connection with the mouthpiece. When the flap opens, the blocking of the slide is removed and the slide, may be pushed into the inhaler while the inhalation is in an early stage of progress.
- a damper mechanism is attached to the slide.
- the damper device provides a first counterforce counteracting the slide motion out of the inhaler body after the slide has been activated and released from its fully retracted position.
- the slide motion out of the inhaler may optionally but preferably be governed and powered by a spring mechanism that provides a spring force, which is reasonably constant.
- the spring-driven motion is balanced by the damper device along the full stroke, or part thereof, of the slide from a second, fully retracted position into a first, fully protruding position. The speed of the slide coming out of the inhaler is thus kept constant.
- the same or a different damper may provide a second counterforce, which may or may not be of the same magnitude as the first counterforce, opposing an applied force pushing the slide back into the inhaler body.
- the applied pushing force may be a manual force provided by a user of the inhaler, or it may be provided by an independent source of power, e.g. in a particular embodiment where the slide is governed and powered by an electric motor device.
- the damper acts to control the speed of the slide motion into the inhaler by providing a suitable, second counterforce formed by the damper, such that the speed of the slide into the inhaler is kept reasonably constant.
- a motorized drive system may replace the spring mechanism and optionally the dampers and/ or the manual pushing force provided by a user.
- This version of moving the slide may e.g. be used where a user has physical handicaps, which restricts or excludes manual use of the device.
- the driving force, necessary for driving the relative motion of the slide in and out of the inhaler may come from any type of power source, e.g. electric, hydraulic, pneumatic, spring, mechanical or manual by a user.
- hand operation by a user is normally preferred, because it offers a low cost, simple and safe administration of any type of inhalable dry powder drug.
- the disclosed method and device may be adjusted to comprise the bringing of the container into a position in the inhaler where the container may be kept in an unopened state prepared for later delivery.
- a movable inhaler member e.g. a slide
- suitable means incorporated in the inhaler e.g. an opener or one or more sharp, piercing instrument.
- opening is triggered by an act of inhalation, such that the enclosed dose may be entrained into inspiration air directly from the container as soon as the container has been opened.
- the time between opening of a selected dose container and inhalation of the enclosed dose is on the order of a split second, which is so short that it is negligible.
- Prior art inhalers allow much longer times between subjecting the selected dose to the ambient atmosphere and an actual inhalation of the dose taking place. Some prior art inhalers have no control over time lapse between breaking the dose container open and a following inhalation. In any case, by the influence of the ambient atmosphere and especially moisture, the dose may decompose rapidly, such that when the user finally gets round to inhaling the dose, it may have deteriorated seriously. The user will then unknowingly get a smaller therapeutic effect than intended.
- dry powder medicament doses need to be protected by an enclosure not only during storage, but also when inserted in an inhaler where the dose and its enclosure are kept in a ready state for delivery in an inhalation at a point in time decided by the user.
- New types of dry powder medicaments not least for systemic treatment, have a rather short expiry date and they are generally quite sensitive to ambient conditions, especially moisture during storage and in use.
- the demands put on dose protection and inhaler devices in handling sensitive doses are therefore much higher than for prior art devices as used e.g. for administering traditional medicaments against respiratory disorders.
- prior art blister packages for dry powder medicaments intended for inhaler use, often use a fairly thin polymeric seal, which can be easily ripped or punched open before the dose is supposed to be inhaled.
- Another common seal is a peelable blister such that the blister is peeled open prior to inhalation of the enclosed dose.
- Yet another type of prior art dose container is the capsule. Capsules are often made by gelatin, but polymers and cellulose and other materials are also used.
- a common problem for prior art blisters and capsules used for dry powder doses for inhalation is that the primary package does not protect sensitive substances from moisture well enough during storage and in use. Minimizing the time the primary package is exposed to the atmosphere and minimizing the time during which the dose is subjected to the ambient atmosphere after opening of the container' are therefore important aspects of inhaler and dose container design.
- a so-called pod as a particular embodiment of a sealed dose container, is to be preferred in an application where the present invention is to be put to use.
- FIG 3 illustrating a sealed dose container 33 in a protective casing 41.
- the container encloses a dose 23, illustrated for the benefit of the reader, although the dose is located under a seal 31.
- Containers providing high quality high barrier seals, such as a pod are particularly suited for use of the present invention. High barrier seals require a pushing force of considerable strength to power opening of the seal. The hand operated slide provides ample power to overcome resistance from the sealing, as opposed to many prior art inhalers.
- Figure 4 illustrating a pod carrying a sealed container in a perspective drawing.
- Figure 4a shows a sealed container 33 (seal 31) put into a protective casing 41 adapted for insertion into a dry powder inhaler.
- Figure 4b shows a top view of the carrier/ container and indicates depositions of dry- powder making up a metered dose inside the container 33 under a seal 31, for the benefit of the reader.
- Figure 4c illustrates a front view of the carrier/ container in Figure 4b.
- the present invention may also advantageously be applied to conventional blister packs and capsules.
- a person skilled in the art may use the disclosure by adapting e.g. when the container seal is to be opened during the course of moving the container from a starting position to an end position and adapting how it is opened to the particular type of container that is selected for use. Such adaptation is still within the scope of the present invention.
- An objective of the present invention is to make the time between opening of the container and delivery of the dose inside as short as possible and to make it impossible for the user to open the container without commencing an inhalation. If an inhalation is broken off prematurely for any reason, then the user will at least be aware that a full dosage may not have been delivered.
- a single dose dry powder inhaler is preferred, because the user may then select a dosage among pre-metered doses, which is well adjusted to the situation and condition the user is in.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Medicinal Preparation (AREA)
- Containers And Packaging Bodies Having A Special Means To Remove Contents (AREA)
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002569343A CA2569343A1 (en) | 2004-06-07 | 2005-06-03 | Securing dose quality of inhalable drug |
BRPI0511891-3A BRPI0511891A (en) | 2004-06-07 | 2005-06-03 | process to ensure the quality of the dose of an inhalable drug |
JP2007527133A JP2008501473A (en) | 2004-06-07 | 2005-06-03 | Guaranteeing the dose quality of inhalable drugs |
MXPA06014265A MXPA06014265A (en) | 2004-06-07 | 2005-06-03 | Securing dose quality of inhalable drug. |
RU2006145654/14A RU2006145654A (en) | 2004-06-07 | 2005-06-03 | PROTECTION OF DOSED MEDICINE FOR INHALATION |
AU2005251670A AU2005251670B2 (en) | 2004-06-07 | 2005-06-03 | Securing dose quality of inhalable drug |
EP05748753A EP1765440A1 (en) | 2004-06-07 | 2005-06-03 | Securing dose quality of inhalable drug |
IL179489A IL179489A0 (en) | 2004-06-07 | 2006-11-22 | Securing dose quality of inhalable drug |
NO20070053A NO20070053L (en) | 2004-06-07 | 2007-01-03 | Ensuring dose quality for inhalable medicine |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0401453-6 | 2004-06-07 | ||
SE0401453A SE528190C2 (en) | 2004-06-07 | 2004-06-07 | Inhaler |
SE0401612-7 | 2004-06-18 | ||
SE0401612A SE530006C2 (en) | 2004-06-18 | 2004-06-18 | Inhaler using tub |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005120616A1 true WO2005120616A1 (en) | 2005-12-22 |
Family
ID=35502846
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/SE2005/000843 WO2005120616A1 (en) | 2004-06-07 | 2005-06-03 | Securing dose quality of inhalable drug |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP1765440A1 (en) |
JP (1) | JP2008501473A (en) |
AU (1) | AU2005251670B2 (en) |
BR (1) | BRPI0511891A (en) |
CA (1) | CA2569343A1 (en) |
IL (1) | IL179489A0 (en) |
MX (1) | MXPA06014265A (en) |
NO (1) | NO20070053L (en) |
RU (1) | RU2006145654A (en) |
WO (1) | WO2005120616A1 (en) |
Cited By (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8424518B2 (en) | 2008-06-13 | 2013-04-23 | Mannkind Corporation | Dry powder inhaler and system for drug delivery |
US9220687B2 (en) | 2008-12-29 | 2015-12-29 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
US9233159B2 (en) | 2011-10-24 | 2016-01-12 | Mannkind Corporation | Methods and compositions for treating pain |
US9241903B2 (en) | 2006-02-22 | 2016-01-26 | Mannkind Corporation | Method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent |
US9283193B2 (en) | 2005-09-14 | 2016-03-15 | Mannkind Corporation | Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents |
US9358352B2 (en) | 2008-06-13 | 2016-06-07 | Mannkind Corporation | Dry powder drug delivery system and methods |
US9364436B2 (en) | 2011-06-17 | 2016-06-14 | Mannkind Corporation | High capacity diketopiperazine microparticles and methods |
US9364619B2 (en) | 2008-06-20 | 2016-06-14 | Mannkind Corporation | Interactive apparatus and method for real-time profiling of inhalation efforts |
US9393372B2 (en) | 2008-06-13 | 2016-07-19 | Mannkind Corporation | Dry powder drug delivery system |
US9630930B2 (en) | 2009-06-12 | 2017-04-25 | Mannkind Corporation | Diketopiperazine microparticles with defined specific surface areas |
US9675674B2 (en) | 2004-08-23 | 2017-06-13 | Mannkind Corporation | Diketopiperazine salts for drug delivery and related methods |
US9700690B2 (en) | 2002-03-20 | 2017-07-11 | Mannkind Corporation | Inhalation apparatus |
US9706944B2 (en) | 2009-11-03 | 2017-07-18 | Mannkind Corporation | Apparatus and method for simulating inhalation efforts |
US9796688B2 (en) | 2004-08-20 | 2017-10-24 | Mannkind Corporation | Catalysis of diketopiperazine synthesis |
US9801925B2 (en) | 1999-06-29 | 2017-10-31 | Mannkind Corporation | Potentiation of glucose elimination |
US9802012B2 (en) | 2012-07-12 | 2017-10-31 | Mannkind Corporation | Dry powder drug delivery system and methods |
US9925144B2 (en) | 2013-07-18 | 2018-03-27 | Mannkind Corporation | Heat-stable dry powder pharmaceutical compositions and methods |
US9943571B2 (en) | 2008-08-11 | 2018-04-17 | Mannkind Corporation | Use of ultrarapid acting insulin |
US9983108B2 (en) | 2009-03-11 | 2018-05-29 | Mannkind Corporation | Apparatus, system and method for measuring resistance of an inhaler |
US10159644B2 (en) | 2012-10-26 | 2018-12-25 | Mannkind Corporation | Inhalable vaccine compositions and methods |
US10307464B2 (en) | 2014-03-28 | 2019-06-04 | Mannkind Corporation | Use of ultrarapid acting insulin |
US10421729B2 (en) | 2013-03-15 | 2019-09-24 | Mannkind Corporation | Microcrystalline diketopiperazine compositions and methods |
US10561806B2 (en) | 2014-10-02 | 2020-02-18 | Mannkind Corporation | Mouthpiece cover for an inhaler |
US10625034B2 (en) | 2011-04-01 | 2020-04-21 | Mannkind Corporation | Blister package for pharmaceutical cartridges |
US11446127B2 (en) | 2013-08-05 | 2022-09-20 | Mannkind Corporation | Insufflation apparatus and methods |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6931952B2 (en) * | 2018-10-04 | 2021-09-08 | 佳吾 犬飼 | Automatic inhaler |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0490797A1 (en) * | 1990-12-13 | 1992-06-17 | Tenax Corporation | Inhalation actuated dispensing apparatus |
US5415162A (en) * | 1994-01-18 | 1995-05-16 | Glaxo Inc. | Multi-dose dry powder inhalation device |
US5595175A (en) * | 1991-08-16 | 1997-01-21 | Sandoz Ltd. | Inhaler for administration of powdery substances |
EP0759306A2 (en) * | 1995-08-11 | 1997-02-26 | Unisia Jecs Corporation | Medicine administering apparatus |
US6422236B1 (en) * | 2000-09-25 | 2002-07-23 | Microdrug Ag | Continuous dry powder inhaler |
US6698425B1 (en) * | 1997-02-07 | 2004-03-02 | Astrazeneca Ab | Powder inhaler |
US6722363B1 (en) * | 1998-06-22 | 2004-04-20 | Astrazeneca Ab | Device for emptying cavities containing powder by means of suction |
-
2005
- 2005-06-03 WO PCT/SE2005/000843 patent/WO2005120616A1/en active Application Filing
- 2005-06-03 MX MXPA06014265A patent/MXPA06014265A/en not_active Application Discontinuation
- 2005-06-03 RU RU2006145654/14A patent/RU2006145654A/en not_active Application Discontinuation
- 2005-06-03 EP EP05748753A patent/EP1765440A1/en not_active Withdrawn
- 2005-06-03 JP JP2007527133A patent/JP2008501473A/en active Pending
- 2005-06-03 BR BRPI0511891-3A patent/BRPI0511891A/en not_active IP Right Cessation
- 2005-06-03 AU AU2005251670A patent/AU2005251670B2/en not_active Expired - Fee Related
- 2005-06-03 CA CA002569343A patent/CA2569343A1/en not_active Abandoned
-
2006
- 2006-11-22 IL IL179489A patent/IL179489A0/en unknown
-
2007
- 2007-01-03 NO NO20070053A patent/NO20070053L/en not_active Application Discontinuation
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0490797A1 (en) * | 1990-12-13 | 1992-06-17 | Tenax Corporation | Inhalation actuated dispensing apparatus |
US5595175A (en) * | 1991-08-16 | 1997-01-21 | Sandoz Ltd. | Inhaler for administration of powdery substances |
US5415162A (en) * | 1994-01-18 | 1995-05-16 | Glaxo Inc. | Multi-dose dry powder inhalation device |
EP0759306A2 (en) * | 1995-08-11 | 1997-02-26 | Unisia Jecs Corporation | Medicine administering apparatus |
US6698425B1 (en) * | 1997-02-07 | 2004-03-02 | Astrazeneca Ab | Powder inhaler |
US6722363B1 (en) * | 1998-06-22 | 2004-04-20 | Astrazeneca Ab | Device for emptying cavities containing powder by means of suction |
US6422236B1 (en) * | 2000-09-25 | 2002-07-23 | Microdrug Ag | Continuous dry powder inhaler |
Cited By (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9801925B2 (en) | 1999-06-29 | 2017-10-31 | Mannkind Corporation | Potentiation of glucose elimination |
US9700690B2 (en) | 2002-03-20 | 2017-07-11 | Mannkind Corporation | Inhalation apparatus |
US9796688B2 (en) | 2004-08-20 | 2017-10-24 | Mannkind Corporation | Catalysis of diketopiperazine synthesis |
US10130685B2 (en) | 2004-08-23 | 2018-11-20 | Mannkind Corporation | Diketopiperazine salts for drug delivery and related methods |
US9675674B2 (en) | 2004-08-23 | 2017-06-13 | Mannkind Corporation | Diketopiperazine salts for drug delivery and related methods |
US9446001B2 (en) | 2005-09-14 | 2016-09-20 | Mannkind Corporation | Increasing drug affinity for crystalline microparticle surfaces |
US10143655B2 (en) | 2005-09-14 | 2018-12-04 | Mannkind Corporation | Method of drug formulation |
US9717689B2 (en) | 2005-09-14 | 2017-08-01 | Mannkind Corporation | Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents |
US9283193B2 (en) | 2005-09-14 | 2016-03-15 | Mannkind Corporation | Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents |
US10130581B2 (en) | 2006-02-22 | 2018-11-20 | Mannkind Corporation | Method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent |
US9241903B2 (en) | 2006-02-22 | 2016-01-26 | Mannkind Corporation | Method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent |
US10342938B2 (en) | 2008-06-13 | 2019-07-09 | Mannkind Corporation | Dry powder drug delivery system |
US9339615B2 (en) | 2008-06-13 | 2016-05-17 | Mannkind Corporation | Dry powder inhaler and system for drug delivery |
US9358352B2 (en) | 2008-06-13 | 2016-06-07 | Mannkind Corporation | Dry powder drug delivery system and methods |
US9446133B2 (en) | 2008-06-13 | 2016-09-20 | Mannkind Corporation | Dry powder inhaler and system for drug delivery |
US9662461B2 (en) | 2008-06-13 | 2017-05-30 | Mannkind Corporation | Dry powder drug delivery system and methods |
US9511198B2 (en) | 2008-06-13 | 2016-12-06 | Mannkind Corporation | Dry powder inhaler and system for drug delivery |
US8636001B2 (en) | 2008-06-13 | 2014-01-28 | Mannkind Corporation | Dry powder inhaler and system for drug delivery |
US10751488B2 (en) | 2008-06-13 | 2020-08-25 | Mannkind Corporation | Dry powder inhaler and system for drug delivery |
US9393372B2 (en) | 2008-06-13 | 2016-07-19 | Mannkind Corporation | Dry powder drug delivery system |
US8912193B2 (en) | 2008-06-13 | 2014-12-16 | Mannkind Corporation | Dry powder inhaler and system for drug delivery |
US9192675B2 (en) | 2008-06-13 | 2015-11-24 | Mankind Corporation | Dry powder inhaler and system for drug delivery |
US10201672B2 (en) | 2008-06-13 | 2019-02-12 | Mannkind Corporation | Dry powder inhaler and system for drug delivery |
US8499757B2 (en) | 2008-06-13 | 2013-08-06 | Mannkind Corporation | Dry powder inhaler and system for drug delivery |
US8424518B2 (en) | 2008-06-13 | 2013-04-23 | Mannkind Corporation | Dry powder inhaler and system for drug delivery |
US9364619B2 (en) | 2008-06-20 | 2016-06-14 | Mannkind Corporation | Interactive apparatus and method for real-time profiling of inhalation efforts |
US10675421B2 (en) | 2008-06-20 | 2020-06-09 | Mannkind Corporation | Interactive apparatus and method for real-time profiling of inhalation efforts |
US9943571B2 (en) | 2008-08-11 | 2018-04-17 | Mannkind Corporation | Use of ultrarapid acting insulin |
US9655850B2 (en) | 2008-12-29 | 2017-05-23 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
US9220687B2 (en) | 2008-12-29 | 2015-12-29 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
US10172850B2 (en) | 2008-12-29 | 2019-01-08 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
US9983108B2 (en) | 2009-03-11 | 2018-05-29 | Mannkind Corporation | Apparatus, system and method for measuring resistance of an inhaler |
US9630930B2 (en) | 2009-06-12 | 2017-04-25 | Mannkind Corporation | Diketopiperazine microparticles with defined specific surface areas |
US9706944B2 (en) | 2009-11-03 | 2017-07-18 | Mannkind Corporation | Apparatus and method for simulating inhalation efforts |
US10625034B2 (en) | 2011-04-01 | 2020-04-21 | Mannkind Corporation | Blister package for pharmaceutical cartridges |
US10130709B2 (en) | 2011-06-17 | 2018-11-20 | Mannkind Corporation | High capacity diketopiperazine microparticles and methods |
US9364436B2 (en) | 2011-06-17 | 2016-06-14 | Mannkind Corporation | High capacity diketopiperazine microparticles and methods |
US9233159B2 (en) | 2011-10-24 | 2016-01-12 | Mannkind Corporation | Methods and compositions for treating pain |
US10258664B2 (en) | 2011-10-24 | 2019-04-16 | Mannkind Corporation | Methods and compositions for treating pain |
US9610351B2 (en) | 2011-10-24 | 2017-04-04 | Mannkind Corporation | Methods and compositions for treating pain |
US9802012B2 (en) | 2012-07-12 | 2017-10-31 | Mannkind Corporation | Dry powder drug delivery system and methods |
US10159644B2 (en) | 2012-10-26 | 2018-12-25 | Mannkind Corporation | Inhalable vaccine compositions and methods |
US10421729B2 (en) | 2013-03-15 | 2019-09-24 | Mannkind Corporation | Microcrystalline diketopiperazine compositions and methods |
US9925144B2 (en) | 2013-07-18 | 2018-03-27 | Mannkind Corporation | Heat-stable dry powder pharmaceutical compositions and methods |
US11446127B2 (en) | 2013-08-05 | 2022-09-20 | Mannkind Corporation | Insufflation apparatus and methods |
US10307464B2 (en) | 2014-03-28 | 2019-06-04 | Mannkind Corporation | Use of ultrarapid acting insulin |
US10561806B2 (en) | 2014-10-02 | 2020-02-18 | Mannkind Corporation | Mouthpiece cover for an inhaler |
Also Published As
Publication number | Publication date |
---|---|
BRPI0511891A (en) | 2008-01-15 |
NO20070053L (en) | 2007-01-03 |
RU2006145654A (en) | 2008-07-20 |
MXPA06014265A (en) | 2007-03-12 |
IL179489A0 (en) | 2007-05-15 |
EP1765440A1 (en) | 2007-03-28 |
AU2005251670B2 (en) | 2010-04-22 |
JP2008501473A (en) | 2008-01-24 |
CA2569343A1 (en) | 2005-12-22 |
AU2005251670A1 (en) | 2005-12-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2005251670B2 (en) | Securing dose quality of inhalable drug | |
US7278426B2 (en) | Securing dose quality of an inhalable drug | |
US7032593B2 (en) | Inhalation device and method | |
AU2001290432B2 (en) | Continuous dry powder inhaler | |
US9974909B2 (en) | Inhalation device and method | |
JP4975251B2 (en) | Unit dose dry powder inhaler | |
AU2001290432A1 (en) | Continuous dry powder inhaler | |
US5692496A (en) | Dry powder medicament inhalator having an inhalation-activated flow diverting means for triggering delivery of medicament | |
WO2008092864A1 (en) | Method and devices for aerosolizing a drug formulation | |
US20060005832A1 (en) | Inhaler using pods | |
WO2008101992A1 (en) | Aerosol generating device with air flow control | |
US20070068524A1 (en) | Inhaler for moisture sensitive drugs | |
KR20070092747A (en) | A foil cutter in a dry powder inhaler and a method for cutting open a container | |
KR20070020550A (en) | Securing dose quality of inhalable drug | |
WO2008101991A1 (en) | Breath actuation mechanism for an aerosol generating device |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 179489 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005251670 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 551570 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 7183/DELNP/2006 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2569343 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12006502454 Country of ref document: PH Ref document number: 200580018400.4 Country of ref document: CN Ref document number: 2007527133 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2006/014265 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005748753 Country of ref document: EP Ref document number: 06130554 Country of ref document: CO |
|
ENP | Entry into the national phase |
Ref document number: 2005251670 Country of ref document: AU Date of ref document: 20050603 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007/00132 Country of ref document: ZA Ref document number: 200700132 Country of ref document: ZA |
|
WWP | Wipo information: published in national office |
Ref document number: 2005251670 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1200700025 Country of ref document: VN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020077000393 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006145654 Country of ref document: RU |
|
WWP | Wipo information: published in national office |
Ref document number: 1020077000393 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2005748753 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: PI0511891 Country of ref document: BR |